Type 2 Diabetes Treated With Insulin Clinical Trial
Official title:
The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Trial: Study Protocol for a Randomized Controlled Trial
The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for six months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.
The DiaTRUST trial is an open-label randomized controlled trial with a six-month trial period. The trial will be conducted at Steno Diabetes Center North Jutland. Patients with T2D on insulin therapy will be randomized (3:1:1) to an intelligent telemonitoring group (intervention), telemonitoring alone (control), or a usual care group (control). Both telemonitoring groups will use an insulin pen, an activity tracker, a CGM, and a smartphone application throughout the trial period. Hospital staff (lab technicians and nurses) will monitor the telemonitoring groups' data and contact the subjects by telephone repeatedly throughout the trial period. For patients assigned to the intelligent telemonitoring group, decision support algorithms will provide hospital staff with insight and data overviews to support treatment evaluation and adjustment throughout the trial. Furthermore, patients in the intelligent telemonitoring group will have access to algorithms through a smartphone application that can provide a risk assessment before bed of nocturnal hypoglycemia. The usual care group will use a blinded CGM for the first 20 days after inclusion, 20 days before the second visit to the trial site, and 20 days before the end of trial and will use a blinded insulin pen for the entire period. The usual care groups' data will not be monitored during the trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04522882 -
Clinical Data Collection for the Closed Loop Development for the Type 2 Diabetes Treatment - DT2_1
|
N/A | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Not yet recruiting |
NCT05185518 -
Assessment of an Integrated Continuous Glucose Monitor and Insulin Injection Port in Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05893797 -
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
|
N/A | |
Completed |
NCT02791295 -
Lifestyle Intervention in Type 2 Diabetes
|
N/A | |
Withdrawn |
NCT04957173 -
Intensive Lifestyle Intervention in Patients With Insulin-treated Type 2 Diabetes: a Pilot Project
|
N/A | |
Not yet recruiting |
NCT05317585 -
Continuous Glucose Monitor Use in Pregnancy
|
N/A | |
Completed |
NCT05372471 -
Efficacy of the Digital Platform for Diabetes Care Compared to Usual Care in Patients Diagnosed With Type 2 Diabetes.
|
N/A | |
Completed |
NCT05111301 -
Control-IQ Technology in Individuals With Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04585191 -
Reducing Treatment Risk in Older Adults With Diabetes
|
N/A | |
Recruiting |
NCT04871438 -
Flash CONtinous Glucose Monitoring in TRansition to Outpatient: Libre for Type 2 Diabetes Mellitus (CONTROL-DM)
|
N/A | |
Completed |
NCT06060743 -
Examining the Effect of Mobile Application on Insulin Use Perception and Self-Management
|
N/A | |
Completed |
NCT04005261 -
C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes
|
||
Terminated |
NCT03980236 -
Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]
|
N/A | |
Completed |
NCT03437525 -
Peer Support in Diabetes Management - Insulin Peer Support
|
N/A | |
Active, not recruiting |
NCT03070106 -
Diabetes: Functional Medicine Approach vs. Usual Care
|
N/A | |
Completed |
NCT02060916 -
Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes
|
Phase 2 | |
Active, not recruiting |
NCT05785832 -
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04945070 -
INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi
|
Phase 4 | |
Recruiting |
NCT05795439 -
The CARING Study: Creating and Restoring Health Through Nutrition Guidance
|
N/A |